HIV cell ther­a­py biotech Ad­dim­mune to go pub­lic via SPAC merg­er; WHO names new Covid-19 'vari­ant of in­ter­est'

Last year
News Briefing

J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

Last year
R&D
Pharma

Ex­clu­sive: As­traZeneca’s out­go­ing R&D chief Mene Pan­ga­los re­flects on a 14-year R&D turn­around and the in­dus­try's ...

Last year
People
R&D

No­vo Nordisk boasts $14.6B in H1 obe­si­ty, di­a­betes sales, but ques­tions linger on broad­er cov­er­age

Last year
Pharma

Galera Ther­a­peu­tics to cut 70% of staff in wake of re­jec­tion for ra­dio­ther­a­py com­pli­ca­tion treat­ment

Last year
Pharma
FDA+

No­vo Nordisk snaps up In­ver­sa­go Phar­ma for up to $1B+ on the back of megablock­buster We­govy sales

Last year
Deals

Astel­las builds its R&D foot­print in Cam­bridge/Boston with an add-on for labs, of­fices

Last year
Bioregnum

Il­lu­mi­na slash­es out­look for 2023, two ex­ec­u­tives de­part

Last year
R&D

Genen­tech, Blue­print tout full ap­proval for Gavre­to in rare type of lung can­cer

Last year
Pharma
FDA+

More lab and man­u­fac­tur­ing space com­ing to the UK's 'Gold­en Tri­an­gle'

Last year
Pharma
Manufacturing

Texas at­tor­ney gen­er­al an­nounces $42.7M set­tle­ment with Take­da, Bax­ter over AD­HD drug 

Last year
Pharma
Law

Genen­tech adopts racial jus­tice lens for new fund­ing that goes be­yond typ­i­cal health eq­ui­ty grants

Last year
Pharma
Marketing

Genen­tech reach­es set­tle­ment with the EPA over haz­ardous waste vi­o­la­tions

Last year
Manufacturing

FDA+ roundup: FDA con­tin­ues to loosen stan­dard of ev­i­dence for nov­el drug ap­provals — JA­MA re­search let­ter

Last year
R&D
FDA+

OTC nalox­one nasal spray to cost about as much as the brand-name, pre­scrip­tion ver­sion

Last year
Pharma

Terns Phar­ma­ceu­ti­cals touts mid-stage suc­cess for NASH drug, stock falls

Last year
R&D

Eli Lil­ly’s Moun­jaro peak sales could now top $68B – an­a­lyst; Elon Musk’s brain-chip com­pa­ny reels in $280M

Last year
News Briefing

Re­gen­eron to buy gene ther­a­py biotech Deci­bel Ther­a­peu­tics in small $109M deal

Last year
Deals
Cell/Gene Tx

SPAC eu­reK­ING ac­quires an­oth­er man­u­fac­tur­er

Last year
Deals
Manufacturing

Mary­land biotech Geor­gia­mune nabs $75M to fund three can­cer, au­toim­mune clin­i­cal tri­als 

Last year
Financing
Startups

Gates-backed study of faster tu­ber­cu­lo­sis drug treat­ments kicks off in South Africa

Last year
R&D

Salarius Phar­ma­ceu­ti­cals lays off over 50% of staff in search for strate­gic al­ter­na­tives

Last year
People

RNA start­up ADARx rais­es $200M from Bain, TCGX to bring RNAi 'to the next lev­el'

Last year
Financing

Flag­ship start­up All­tr­na rais­es $109M for tR­NA ther­a­pies that re­store miss­ing pro­teins

Last year
Financing
First page Previous page 298299300301302303304 Next page Last page
A service from the Financial Times